Gilead Stock News

(Agency report) American biopharmaceutical company Gilead Sciences Inc. has issued a nationwide recall of two lots of its coronavirus treatment drug Remdesivir due to the presence of glass particulates, the

Gilead said Friday that it would carry out a voluntary recall of two lots of the coronavirus drug in the U.S. after determining that some vials were contaminated with glass.

Gilead Sciences announced a nationwide recall of 55,000 vials of its COVID-19 treatment drug remdesivir due to the "presence of glass particulates."

JJJ Advisors Inc. boosted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 29.6% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 757 shares of the biopharmaceutical companys stock after acquiring an additional 173 shares during the quarter. JJJ Advisors Inc.s holdings in []

A pharmaceutical manufacturer recalled thousands of vials of its COVID-19 antiviral drug remdesivir after an investigation found they were contaminated with glass particles.

Gilead Sciences Inc. is recalling 55,000 vials of the COVID-19 drug remdesivir in the US after after a complaint about glass particles was confirmed by a company investigation.

Unison Advisors LLC decreased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 19.8% during the 3rd quarter, Holdings Channel.com reports. The firm owned 20,535 shares of the biopharmaceutical companys stock after selling 5,055 shares during the period. Unison Advisors LLCs holdings in Gilead Sciences were worth $1,435,000 at the end of the most []

Gilead Sciences has stagnated over the last 5 years while spending significant capital to try to build a new business.

Two big biotechs and one smaller one that could be winners over the long term.

Pflug Koory LLC decreased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 15.6% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 2,695 shares of the biopharmaceutical companys stock after selling 500 shares during the quarter. Pflug Koory LLCs holdings in Gilead Sciences []

Gilead Sciences, Inc. (GILD) Management Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference (Transcript)

Seelaus Asset Management LLC raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.9% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,110 shares of the biopharmaceutical companys stock after buying an additional 425 shares during the quarter. Seelaus Asset Management LLCs []

Stratos Wealth Partners LTD. decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 91,723 shares of the biopharmaceutical company’s stock after selling 3,130 shares during the period. Stratos Wealth Partners […]